| Summary: | Hongzhen Zhong,1,* Tianbiao Zhou,1,* Hongyan Li,2,* Zhiqing Zhong1,* 1Department of Nephrology, The Second Affiliated Hospital, Shantou University Medical College, Shantou, China; 2Department of Nephrology, Huadu District People’s Hospital of Guangzhou, Southern Medical University, Guangzhou, China *These authors contributed equally to this work Introduction: The purpose of this study was to analyze the effects of hypoxia-inducible factor (HIF) stabilizers on anemia in non-dialysis-dependent (NDD) and dialysis-dependent (DD) chronic kidney disease (CKD) patients.Methods: Published studies were extracted from PubMed, China Biological Medicine Database (CBM), Wanfang database, and Cochrane Library on March 10, 2018, and relevant studies were pooled and included in a meta-analysis. Data on hemoglobin (Hb), ferritin, and hepcidin levels, total iron-binding capacity (TIBC), and incidence of adverse events (AEs) were extracted and pooled using Review Manager Version 5.3.Results: Data from nine selected studies were extracted. Meta-analysis of the included studies showed that HIF stabilizers reduced ferritin and hepcidin levels and increased Hb level and TIBC in NDD-CKD patients. However, HIF stabilizers only increased TIBC, and did not affect ferritin, hepcidin, and Hb levels in DD-CKD patients. Furthermore, no notable differences in AEs and severe AEs between NDD-CKD and DD-CKD patients were detected.Conclusion: HIF stabilizers are effective for the treatment of anemia in NDD-CKD patients and safe for short-term use. Keywords: hypoxia-inducible factor stabilizer, anemia, chronic kidney disease, meta-analysis
|
|---|
